Daily Bulletin

Men's Weekly

.

  • Written by Heidi Cuthbert


7 May 2018: Race Oncology Limited (“RAC”) released today a video interview with the Company’s new non-executive director, Dr John Cullity.

Dr Cullity trained as a haematology oncologist and became a specialist in the area of leukaemia. He has also held senior roles with Sanofi-Aventis and Schering-Plough in the US.

Based in New York, Dr Cullity now focuses on M&A and licensing transactions in the biopharma industry.

Commenting on Race Oncology’s first drug, Bisantrene, Dr Cullity said: “There is substantial opportunity for Bisantrene which is led by its activity in acute myeloid leukaemia.”

“Bisantrene has been shown to be active through immune-oncology pathways, which are so relevant to blockbuster agents that are currently being marketed by major pharmaceutical companies,” noted Dr Cullity.

“Additionally, it has unparalleled safety, particularly cardiac safety, which is so relevant and much sought-after by doctors within the anthracycline class.

He concluded: “Altogether, it’s a compelling package.”

In terms of the specific value he brings to the Race board, Dr Cullity noted: “I can help in several ways – firstly, through the evaluation of transactions as they come to light for Bisantrene with mid-to-large pharmaceutical companies.”

“Secondly, as the company considers additional assets that it might bring to build further investor value, I can assist with related assessment and negotiation.”

About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company’s first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of big pharma mergers.

 



g

Wang Chuanfu Attends BYD Harmony’s 100th Overseas Store Opening

Dignitaries inaugurate the new store On July 12, 2025, Melbourne, the vibrant pearl of the southern hemisphere, Chairman and President of BYD Co., Ltd. Mr. Wang Chuanfu inaugurated and awarded the ...

Daily Bulletin - avatar Daily Bulletin

Strategic Global Expansion Moves to Overcome the Growth Challenges

Photo by Gabrielle Henderson on Unsplash Australia's startup ecosystem is having a moment in the sun. Out of 1,257 unicorns globally, eight hail from Australia. Yet, trade and economic policy uncerta...

Daily Bulletin - avatar Daily Bulletin

What Is a Restaurant Point of Sale System and Why Every Eatery Needs One

The commercial dining industry is incredibly fast-paced and constantly needs upgrades to attract the target audience. Every entrepreneur in this sector, without exception, faces numerous challenges...

Daily Bulletin - avatar Daily Bulletin

VR Training in Australia – Virtual Reality Safety Training Companies

In today’s rapidly evolving workplaces, Australian organisations are turning to immersive learning tools like VR to handle specialised needs such as virtual reality safety training companies. Take ...

Daily Bulletin - avatar Daily Bulletin

How to Extend the Lifespan of Your Conveyor System

It’s easy to forget your conveyor is even there, until it stops. And when it does, you’re in a world of delayed orders, unexpected downtime, and one very expensive headache. But the good news is tha...

Daily Bulletin - avatar Daily Bulletin

Virtual CFO Hiring Checklist: 10 Expert Tips in Australia

Hiring a Virtual CFO (VCFO) is no longer just reserved for large corporations. In today’s business environment, where agility, compliance, and strategic foresight are essential, Australian startups...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals